ARCHIVES

Drug Development: FDA Grants Breakthrough Therapy Designation to CTL019 In ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 28 | July 11, 2014

Download PDF Visit The Full Archive

Related Articles

As ImClone Investigation Continues, FDA Combines Drugs, Biologics Review; Memo Describes “Lengthy Process” That Led To FDA Decision; Oncology Community Praises FDA Move

September 13, 2002

NCI To Proceed With Guidelines Unless Board Strongly Disagree

May 9, 1980

NCCS Networker Volume 9 Issue 4, Winter 1995

January 12, 1995

Tight Budget, Turf Battles Kill One Project, Threaten Popular CGP Clinical Trials Effort

July 4, 1986

Evidence Supports Screening Younger Women, Expert Says

September 24, 1993

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014